Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swedish research based pharmaceutical firm Medivir has started a Phase I clinical trial of the nucleotide polymerase inhibitor AL-704 for treatment of patients with hepatitis C.
Subscribe to our email newsletter
AL-704 is a nucleotide based NS5B polymerase inhibitor also known as JNJ-54257099, by Alios Biopharma, part of the Janssen Pharmaceutical Companies.
It is intended for the treatment of chronic hepatitis C virus (HCV) infection in combination with other direct acting antiviral agents.
In 2008, Medivir entered a research & development agreement in the field of HCV polymerase with Janssen Products.
AL-704 is the second candidate drug developed under this deal that enters into clinical development.
The randomized, double-blind, placebo-controlled, three-part Phase I trial of orally administered AL-704 will evaluate the safety, tolerability and pharmacokinetics of single ascending doses and food-effect in healthy volunteers, and multiple doses in subjects with chronic hepatitis C infection of genotype 1 and 3.